将投中网设为"星标⭐"，第一时间收获最新推送 瑞凯以长期主义强势看多中国生物医药行业。 来源丨投中网 中国生长激素市场规模2023年达116亿元，预计2030年将增长至286亿元，其中长效剂型（每周注射 一次）占比将超70%。 在这个百亿级大市场中，长春高新旗下的金赛药业几乎一家独大，占据超过80%的市场份额，手握一 系列大单品（尤其长效剂型目前只有金赛增唯一在售），长春高新一度市值超过2000亿人民币，被 称为"东北药茅"。 时至今日，一位颇有潜力的破局者——维昇药业（VISEN Pharmaceuticals）杀入，核心产品"隆培促 生长素（lonapegsomatropin）"，采用每周一次的长效给药方案，相较于传统短效剂型需每日注射， 极大提升了患者依从性，临床数据显示在安全性相当的前提下，疗效均优于现有短效剂型，而且25 周和52周的数据均优于长春高新旗下金赛。 更重要的是，该产品在美国和欧洲市场的名称是Skytrofa，已由维昇药业的母公司Ascendis Pharma （ASND.US）成功商业化，据Evaluate Pharm预测，到2026年销售额将达到15亿美元。Ascendis凭 此在纳 ...

Industry Investment Rating - The report assigns a "Leading" investment rating to the pharmaceutical industry, indicating an expectation of attractive performance relative to the benchmark index over the next 12 months [1]. Core Insights - The strong foundation project in healthcare is expected to create new opportunities in the medical device sector, with a focus on innovative drugs, prescription drugs, and CXO during the annual report season [1][4]. - The report highlights the potential benefits of the healthcare strong foundation project, which aims to enhance grassroots medical services and infrastructure, thereby driving growth in the medical device market [4][6]. - The report suggests that the pharmaceutical sector still has significant room for recovery, given the favorable policies expected to be implemented in the second half of 2025, alongside the current low valuations of the sector [4]. Summary by Sections Market Performance - The Hang Seng Index fell by 3.2% during the week of March 6-12, 2025, while the Hang Seng Healthcare Index decreased by 2.8%, ranking 10th among 12 industry indices [4][8]. - Sub-sectors such as biotechnology, life sciences tools and services, and pharmaceuticals experienced declines of 1.1%, 1.3%, and 1.6% respectively [4]. Investment Recommendations - The report recommends focusing on sub-sectors with potential for above-expectation performance, including innovative drugs, prescription drugs, and CXO [4]. - Specific companies highlighted for their growth potential include 康方生物 (CanSino Biologics), 信达生物 (Innovent Biologics), and 传奇生物 (Legend Biotech), which are expected to benefit from short-term catalysts and high growth [4][6]. - The report also emphasizes the importance of AI in healthcare, suggesting investment in companies with clear applications in health management [4]. Company Updates - 康方生物 has completed patient enrollment for its Phase III clinical trial of 卡度尼 (AK104) for high-risk liver cancer [6]. - 云顶新耀 has initiated the first human trial for its mRNA personalized cancer vaccine EVM16 [7]. - 翰森制药 received approval for a new indication for 阿美替尼 (Amehtinib) for non-small cell lung cancer [7]. - 中国生物制药's injection of 甲磺酸艾立布林 has been approved by the FDA for metastatic breast cancer treatment [7]. Valuation Overview - The report provides a valuation summary indicating that the pharmaceutical sector has a TTM P/E ratio of 11.3, while other sectors like life sciences tools and services have a TTM P/E of 7.3 [13].

Summary of Key Points from the Conference Call Industry or Company Involved - The conference call discusses the cryptocurrency market, particularly focusing on Bitcoin, and its relationship with traditional assets like gold and the stock market. It also touches on the Hong Kong stock market as a platform for global capital allocation. Core Points and Arguments Bitcoin as an Alternative Asset - Bitcoin has transitioned from being primarily driven by retail speculation to being influenced by institutional investment and U.S. dollar liquidity, showing a negative correlation with U.S. real interest rates [3][4][5] - The price of Bitcoin is highly correlated with mining costs, which increase with greater computational power [3][4] - Bitcoin's long-term annualized return can exceed 80%, but it also exhibits a volatility rate over 60%, posing challenges for institutional investors [5][6] Relationship with Gold - Gold prices are influenced by multiple factors, including central bank purchases, U.S. fiscal deficits, and market dynamics, with a mid-term target price of $3,100 to $3,200 [3][19] - Central bank gold purchases have altered the supply-demand dynamics in the gold market, particularly with China reducing U.S. Treasury holdings while increasing gold reserves [21][22] - The creditworthiness of the U.S. dollar significantly impacts gold prices, with high fiscal deficits undermining dollar credibility and pushing gold prices higher [23][24] Market Dynamics and Risks - Bitcoin faces risks from technological vulnerabilities, potential competition from superior cryptocurrencies, and significant sell-offs by large holders (whales) [8][9] - The correlation between Bitcoin and the Nasdaq index has strengthened since 2020, indicating that both are influenced by macro liquidity conditions [5][15] - The tightening of U.S. dollar liquidity is expected to support gold and Bitcoin prices in the near term [12] Hong Kong Stock Market - The Hong Kong stock market is positioned as a crucial platform for global capital allocation, with mechanisms like ETF cross-listing facilitating cross-border investments [35][36] - The market has seen a significant increase in cross-border investment activities, with a notable rise in the proportion of southbound capital [35][41] - The future of the Hong Kong market is expected to be shaped by its role as an international financial center, with ongoing developments in ETF products and cross-border investment channels [39][40] Other Important but Possibly Overlooked Content - The potential for AI technology to enhance productivity in various sectors, including logistics and transportation, is highlighted as a significant trend that could impact market dynamics [55] - The ongoing geopolitical tensions and their effects on gold demand and pricing are noted, with a focus on how these factors could influence investment strategies [28][29] - The historical context of gold price fluctuations and the factors leading to significant market corrections are discussed, providing insights into potential future trends [32][34] This summary encapsulates the key insights from the conference call, focusing on the cryptocurrency market, particularly Bitcoin, its relationship with gold, and the evolving role of the Hong Kong stock market in global capital allocation.

Market Performance - The Hong Kong stock market has shown strong upward momentum, with the Hang Seng Index increasing nearly 30% and the Hang Seng Tech Index rising over 40% since January 14 this year [3] - Notable stock performances include Alibaba Health up over 70%, SMIC, Alibaba, and Kuaishou up over 60%, and Xiaomi up over 50% year-to-date [3] Investment Trends - There is a divergence in investor sentiment, as some ETFs focused on Hong Kong stocks have seen a decrease in circulating shares, while others have experienced an increase [5] - The China AI model breakthroughs have improved market expectations, making Hong Kong stocks more attractive to investors [3] Fund Flow Analysis - Southbound capital inflow has been significant, with net inflows reaching HKD 339.51 billion this year and a cumulative net inflow of approximately HKD 4.04 trillion since the launch of the Stock Connect [4] - The performance of ETFs varies, with the Huaxia Hang Seng Internet Technology ETF seeing a decrease of 207.56 million shares since the beginning of the year, while the Fortune CSI Hong Kong Internet ETF increased by 115.58 million shares [6][8] Structural Characteristics - The current market rebound is characterized by a focus on technology stocks, which have outperformed other sectors in terms of both price increase and trading volume [4] - The optimism surrounding technology trends and AI developments is seen as a key driver for future market performance, although caution is advised regarding short-term catalysts and external risks [9][10]

Core Viewpoint - The article highlights the significant growth and potential of Chinese innovative drugs in the global market, emphasizing that Chinese companies are increasingly recognized for their capabilities in drug development and commercialization, which poses a challenge to traditional pharmaceutical giants in the U.S. [2][3] Group 1: Market Trends - In 2024, nearly 100 deals involving Chinese innovative drugs were reported, with a total disclosed amount close to $60 billion [3] - Major pharmaceutical companies are shifting their focus towards acquiring innovative drugs from China due to the high costs associated with developing new drugs in the U.S. [4] - The trend of "NewCo" transactions has gained traction, allowing Chinese companies to establish new entities overseas to attract higher valuations and funding [7][8] Group 2: Buyer Preferences - Multinational corporations (MNCs) are increasingly interested in early-stage projects, contrary to the stereotype that they prefer stable, late-stage products [5] - Buyers are looking for "clean" transactions, focusing on individual products rather than the entire technology platform of a biotech company [5] - The willingness of MNCs to source innovative drugs from China is becoming an open secret, driven by the cost-effectiveness of Chinese products [4][5] Group 3: Challenges and Considerations - The NewCo model, while promising, has limitations as it often involves products that are not core to the original company’s pipeline, leading to lower upfront payments [8] - The cultural and operational challenges of establishing trust and collaboration in international markets are significant for Chinese companies entering NewCo transactions [9] - The financial sustainability of biotech firms during the waiting period for potential acquisitions or IPOs remains a concern, as they may face cash flow issues before realizing returns [8][9]

而这个美丽优先政策， 你把它视作德州政策的放大版就行了 ，反正这位德州州长也是共和党保守派，一丘之貉，政策也是一脉相承的。 而彼时是什么惨状呢？消息传来后，A股5000多家上市公司，当天跌幅3%以上的占70%，跌幅5%以上的有1400家，然后再看看今天，你就说硬 不硬吧？ 所以，可以看到，此时的心气，和彼时的心气，确实已经完全不同了。 今天表面看有点像股债双杀，但实际上，仅仅是债券吃了一碗大面而已，债券的事下半部分再说。 先说A股，今天成交额继续破2万亿，上涨的股票超过50%，wind全A跌幅不到0.1%， 而之所以说今天A股非常硬 ，主要是因为咱们这边开盘 前，有个实质上比较huge的外围利空。 那就是太平洋对岸，周五出台的 America First Investment Policy，为了文章的安全，我就把它翻译为" 美丽优先 政策 " 吧。 我带大家回忆一下， 去年11月21日，德州州长 ，发布了多项行政命令，限制对咱的投资，并要求州政府所属机构审查在华投资，大家应该多少 有点印象吧？忘了也没事，咱每天写公众号，一搜就能搜到当天的文章，《 找了一下今天大跌的原因 》，里面有提到，可以进去回顾一下。 不 ...

适时转身。 投资界（PEdaily.cn）旗下，专注并购动态 以下文章来源于并购最前线 ，作者岳笑笑 并购最前线 . 作者 I 岳笑笑 先来看并购的两位主角—— 根据公开资料，收购方奥浦迈是一家专门从事细胞培养产品与服务的科技型企业，曾在 20 22年登陆科创板，被称作"细胞培养基CDMO第一股"。巅峰时期，公司市值一度超过 10 0亿元，但随后股价持续下滑，如今市值浮动在45亿元左右。 宣布收购前，奥浦迈业绩持续下滑。2 02 2年及2023年，公司的营业收入分别为2.94亿 元、2. 4 3亿元；毛利率分别为 6 3. 9 7%、58.85%；归母净利润分别为1.05亿元、0. 5 4亿 元。前不久发布的业绩预告更是显示，公司2024年预计实现归母净利润0.20亿元，同比 下降62 . 37%。 奥浦迈迫切需要一条出路。于是在去年11月，公司公告拟出资不超过3亿元参设产业投资 基金，对中国境内生物制造、制药设备和耗材、生物医药等领域的早中期项目和并购项 目进行投资活动。此前奥浦迈还称，投资并购是公司一直想做的事情，具体的进展会根 据公司实际情况推进。 报道 I 投资界-并购最前线 医药圈又诞生一例并购案。 ...

以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 一个伟大的开端。 作者 | 阿基米德君 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 这个冬天太长了。在遥远的2021年夏天，所有人都不会想到医药下行周期会超过3年半，以致于最有耐心的坚守者也濒临崩溃。 参考率先见底的CDMO，当所有负面因素都充分入价后，任何细微的边际改善都将带来巨大弹性。从底部挣扎起来，药明康德反弹约 60% 药明生物反弹约110%，药明合联一度逼近历史新高。 不要指望惊天大逆转，但细微的边际改善是可期待的，这已经足矣。 2024Q4，全部公募基金对医药板块的持仓比例为8.58%，环比下降1.08pct，已超过2022Q3全部基金持仓的低点位（9.37%）， 下降至历史最低位置，意味着任何细微的增量资金都将带来弹性。 寒冰融化。在支付端，单一支付体系即将破局，多元化支付体系将在年内初步建立，而且在用药群众对药效日益关切的推动下，集 采、医保谈判有望转向控费与质控的平衡；在融资端，未盈利生物科技企业 ...

Investment Rating - The report maintains a "BUY" rating for WuXi Biologics, with a target price raised from HK$22.88 to HK$24.24, indicating a potential upside of 36.6% from the current price of HK$17.74 [3][8]. Core Insights - WuXi Biologics added 151 new projects in 2024, the highest in its history, with over half from the US, showcasing strong global competitiveness and client trust [1][8]. - The company is set to receive US$140 million in near-term payments from enabling discovery services for 7 global projects in 2024, highlighting lucrative milestone income [1][8]. - The Ireland site is on track to achieve breakeven in 2025, and the company plans to expand its drug substance capacity significantly, with a focus on establishing a comprehensive global production network [1][8]. Financial Summary - Revenue is projected to grow from RMB 17,034 million in FY23A to RMB 20,687 million in FY25E, reflecting a year-on-year growth of 13.4% [2][18]. - Adjusted net profit is expected to increase from RMB 4,739 million in FY24E to RMB 5,358 million in FY25E, representing a growth of 13.0% [2][18]. - The adjusted EPS is forecasted to rise from RMB 1.15 in FY24E to RMB 1.30 in FY25E, with a P/E ratio decreasing from 14.3x in FY24E to 12.7x in FY25E [2][18]. Project Pipeline and Growth - The company’s project pipeline now includes 817 projects, with a significant increase in process performance qualification (PPQ) projects expected to grow by 31% YoY to 101 in 2025 [1][8]. - WuXi Biologics completed 77 PPQ projects in 2024, marking a 26% increase year-on-year, indicating strong momentum for future growth in CMO revenue [1][8]. Overseas Operations - The Ireland biologics facility has shown strong client demand trends, successfully completing multiple 16k-liter PPQ batch productions, supporting profitability targets for 2025 [1][8]. - WuXi Biologics is constructing a new 36k-liter drug substance capacity facility in the US, aiming to expand total drug substance capacity to 491k liters, with approximately 49% located overseas [1][8].

Investment Rating - The report maintains a "Buy" rating for WuXi Biologics, reflecting a positive outlook based on demand recovery and growth potential [4][28]. Core Insights - WuXi Biologics achieved a record addition of 151 new projects in 2024, with over half coming from the United States, indicating strong global competitiveness and client trust [2][3]. - The company expects revenue and adjusted profit (excluding minority interests) to grow by 5%-10% in 2024, with accelerated growth anticipated in 2025 [1][4]. - The unique CRDMO business model continues to drive significant milestone revenue, with $140 million in recent payments expected from seven global projects [3][4]. - The company is expanding its global manufacturing network, with a focus on achieving breakeven at its Ireland site in 2025 and increasing drug substance capacity in the U.S. [3][4]. Financial Summary - Revenue is projected to grow from RMB 18,236 million in FY24E to RMB 20,687 million in FY25E, representing a 13.4% increase [5][12]. - Adjusted net profit is expected to rise from RMB 4,739 million in FY24E to RMB 5,358 million in FY25E, reflecting a 13.0% growth [5][12]. - The adjusted earnings per share (EPS) is forecasted to increase from RMB 1.15 in FY24E to RMB 1.30 in FY25E [5][12]. Target Price Adjustment - The target price has been raised from HKD 22.88 to HKD 24.24 based on a discounted cash flow (DCF) model, with a weighted average cost of capital (WACC) of 9.64% and a terminal growth rate of 2.0% [4][6].